Dark Forest Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Dark Forest Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-45,758	Closed	-$1.33M	–	796
2025 Q4	$1.33M	Buy	45,758 +18,391	+67%	+$471K	0.06%	555
2025 Q3	$516K	Buy	+27,367	New	+$432K	0.02%	919
2024 Q4	–	Sell	-16,817	Closed	-$156K	–	929
2024 Q3	$156K	Sell	16,817 -10,795	-39%	-$107K	0.02%	899
2024 Q2	$257K	Buy	27,612 +6,362	+30%	+$57.5K	0.05%	491
2024 Q1	$211K	Buy	+21,250	New	+$159K	0.04%	604
2023 Q4	–	Sell	-74,293	Closed	-$394K	–	494
2023 Q3	$394K	Buy	+74,293	New	+$632K	0.03%	803

Other funds holding ARQT

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return